AACR 2024: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favourable safety profile in…
Browsing: AACR
AACR 2024: Immunotherapy combination before surgery improves pancreatic cancer outcomes
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center (USA) investigators suggests that…
AACR 2024: Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators (USA), a novel…
AACR 2024: Novel immunotherapies show promise for patients with kidney cancer and for solid organ transplant recipients with skin cancer
Researchers from The University of Texas MD Anderson Cancer Center, USA, presented encouraging findings today from…
AACR Preview
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest breakthroughs and cutting-edge science…
AACR 2023: SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma
Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of…
AACR 2023: Protein a potential new target for breast cancer treatment
Researchers in Jun-Lin Guan’s lab in UC’s Department of Cancer Biology found a potential combination…
AACR 2023: Research finds oncogene over-expressed in head and neck cancer
Susan Waltz, PhD, studies the role of a gene that helps accelerate cancer growth called…
AACR 2023: Single-cell study uncovers distinct immunosuppressive tumour microenvironment in brain metastases from kidney cancer
In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest…
AACR 2023: Researchers discover pathway critical for lymphoma development
MYC proteins are important regulators of cancer cell growth, proliferation and metabolism through their ability…